Presentation (CTI)

OBJECTIVES: In Chile, at least 15.4% of people over 40 years of age have some degree of CKD which is associated with a negative impact on quality of life, reduction in life expectancy, and economically represented around 22% of the Explicit Health Guarantees (GES) budget in 2019. We aim to estimate the economic burden of CKD in Chile´s private market (ISAPRES) using RWD, and assess the potential impact of adding a SLGT2i to the standard treatment regimen
METHODS: we used anonymized individual patient data (IPD) from the Chilean Superintendency of Health (2016-2022) to assess CKD-related healthcare utilization among ISAPRES beneficiaries. Healthcare services and medical leave records were used to estimate the annual per-patient economic burden by CKD stages. The potential cost impact of adding dapagliflozin, a SGLT2i inhibitor, was estimated based on its expected effect on slowing CKD progression. All costs were converted to USD using an exchange rate of CLP 914 = USD 1
RESULTS: we identified 4,010 CKD patients in ISAPRES. Of these, 1,122 (28%) were in the “CKD prevention or stage 1-3” group, 813 (20%) in “stage 4-5 without dialysis”, and 2,075 (52%) in “CKD with dialysis”. The corresponding annual per-patient costs were USD 3,906, USD 8,072, and USD 27,727, respectively. Over a 5-year horizon, adding dapagliflozin was estimated to reduce total costs by approximately USD 3 million, due to delayed progression to more severe CKD stages
CONCLUSIONS: based on RWD an average CKD patient in ISAPRES is associated with an annual cost USD 17,077. The cost per patient increased accordingly stages progression [USD 3,906 TO USD 27,727]. Dialysis represents a substantial economic burden and should be prioritized in healthcare planning. Interventions that delay disease progression, such as incorporating dapagliflozin into CKD management, could yield meaningful cost savings and should be considered by policymakers